We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

17 hedge funds and large institutions have $33.7M invested in Akari Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 18 → 17 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

40% less capital invested

Capital invested by funds: $56M → $33.7M (-$22.4M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
+$7.8K
2
TRCT
Tower Research Capital (TRC)
New York
+$7.8K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$1.17M
2
EC
EcoR1 Capital
California
-$856K
3
ACP
Acuta Capital Partners
California
-$93.6K
4
UBS Group
UBS Group
Switzerland
-$31.2K
5
TI
Turner Investments
Pennsylvania
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$9.79M – – –
VC
2
Vivo Capital
California
$4.49M – – –
BBA
3
Baker Bros. Advisors
New York
$4.23M – – –
NMC
4
NEA Management Company
Maryland
$3.85M – – –
VMI
5
VHCP Management II
New York
$3.14M – – –
QF
6
QVT Financial
New York
$1.83M – – –
FCMI
7
Foresite Capital Management III
California
$1.68M – – –
VM
8
VHCP Management
New York
$1.35M – – –
BC
9
Boxer Capital
California
$1.19M – – –
RCM
10
RA Capital Management
Massachusetts
$970K -$1.17M -150 -51%
GTC
11
Ghost Tree Capital
New York
$397K – – –
Deutsche Bank
12
Deutsche Bank
Germany
$199K – – –
ACP
13
Acuta Capital Partners
California
$197K -$93.6K -12 -29%
UBS Group
14
UBS Group
Switzerland
$189K -$31.2K -4 -13%
SM
15
Sabby Management
Florida
$148K – – –
ACH
16
ArrowMark Colorado Holdings
Colorado
$7K +$7.8K +1 New
TRCT
17
Tower Research Capital (TRC)
New York
$7K +$7.8K +1 New
Morgan Stanley
18
Morgan Stanley
New York
$2K – – –
EC
19
EcoR1 Capital
California
– -$856K -79 Closed
DCM
20
DAFNA Capital Management
California
– -$6K -1 Closed
TI
21
Turner Investments
Pennsylvania
– -$13K -1 Closed

AKTX Hedge Fund Activity: Q3 2016 in Review

17 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2016, worth a combined $33.7M — down 40% from $56M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AKTX and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $7.8K. The largest seller was RA Capital Management, cutting an estimated $1.17M.

  • 17 institutional investors held Akari Therapeutics (AKTX) as of Q3 2016, down from 18 in Q2 2016.
  • Funds reported $33.7M of Akari Therapeutics stock for Q3 2016, down 40% quarter-over-quarter.
  • 2 funds opened new Akari Therapeutics positions in Q3 2016 and 3 closed out, a net change of -1 holder.
  • The largest Akari Therapeutics buyer in Q3 2016 was ArrowMark Colorado Holdings, an estimated $7.8K added.
  • The largest Akari Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $1.17M sold.

Based on aggregated 13F filings for Q3 2016.